Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab with mFOLFOX6 and HLX04 in MSS mCRC
NCT06491355Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of serplulimab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Progression-Free Survival up to 100 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06491355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491355.